Revenue, last quarter
$0
Net income
−$85.8M
−49.3% vs same quarter last year
EPS, diluted
−$0.76
−16.9% vs same quarter last year
Operating cash flow
−$60.8M
−50% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $6.9M | −$212.4M |
| FY24 | $9M | −$293M |
| FY23 | $14M | −$106.8M |
| FY22 | - | −$36.9M |
| FY21 | - | −$24.7M |
| FY20 | - | −$17.8M |
| FY19 | - | −$10.4M |
| FY18 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −3228.8% | −3060% |
| FY24 | −3382.4% | −3240.4% |
| FY23 | −781.4% | −761.9% |
| FY22 | - | - |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$200.6M |
| FY24 | −$118M |
| FY23 | −$8.4M |
| FY22 | −$28.9M |
| FY21 | −$18.3M |
| FY20 | −$12.7M |
| FY19 | −$9.8M |
| FY18 | - |
- Immunome
- Healthcare median
Show the numbers
| Year | Immunome | Healthcare median |
|---|---|---|
| FY25 | −3060% | −30.6% |
| FY24 | −3240.4% | −47% |
| FY23 | −761.9% | −58% |
| FY22 | - | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |
| FY19 | - | −46.3% |
| FY18 | - | −49.6% |